



IN THE CLAIMS

Please amend the claims as follows:


Claim 1 (Currently Amended): A compound having a general structure represented by Formula I, Formula II, or Formula III;



Formula I



Formula II



Formula III

wherein n is an integer selected from 0 to 2;

R₁ and R₂ are each independently a member selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, hetaryl, aralkyl, hetaralkyl, alkyl substituted with at least one substituent, aryl substituted with at least one substituent, hetaryl substituted with at least one substituent, aralkyl substituted with at least one substituent, and hetaralkyl substituted with at least one ~~substituent~~ substituent;

R₃ is a member selected from the group consisting of hydrogen, alkyl, alkenyl, aralkyl, alkyl substituted with at least one substituent, aralkyl substituted with at least one substituent, CO-R₅, SO₂-R₅, CO-O-R₅, CO-N-R₄, and R₅; and

R₄ and R₅ are each independently a member selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, alkyl substituted with at least one substituent, cycloalkyl substituted with at least one substituent, aryl substituted with at least one substituent, and aralkyl substituted with at least one substituent.

Claim 2 (Currently Amended): ~~A compound~~ The compound according to Claim 1, with reference to R₁₋₅, whenever the following are used;

alkyl is a straight or branched chain C₁₋₁₅ alkyl;

cycloalkyl is a C₃₋₈ cycloalkyl;

alkenyl is a straight or branched chain C₂₋₁₈ alkenyl;

aralkyl is a carbomonocyclic aromatic or carbobicyclic aromatic substituted with a straight or branched chain C₁₋₁₅ alkyl; and

substituent is selected from the group consisting of nitro, hydroxy, cyano, carbamoyl, mono- or di-C₁₋₄ alkyl-carbamoyl, carboxy, C₁₋₄ alkoxy-carbonyl, sulfo, halogen, C₁₋₄ alkoxy, phenoxy, halophenoxy, C₁₋₄ alkylthio, mercapto, phenylthio, pyridylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, amino, C₁₋₃ alkanoylamino, mono- or di-C₁₋₄ alkylamino, 4- to 6-membered cyclic amino, C₁₋₃ alkanoyl, benzoyl, and 5 to 10 membered heterocyclic.

Claim 3 (Currently Amended): ~~A compound~~ The compound according to claim 1, with reference to R₁₋₅, whenever the following are used;

aryl is a carbomonocyclic aromatic or carbobicyclic aromatic;

hetaryl is a heteromonocyclic aromatic or heterobicyclic aromatic containing 1 to 6 hetero-atoms selected from oxygen, sulfur and nitrogen;

aralkyl is a carbomonocyclic aromatic or carbobicyclic aromatic substituted with a straight or branched chain C₁₋₁₅ alkyl; and

substituent is a member selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ alkoxy, C₁₋₄ alkylthio, hydroxy, carboxy, cyano, nitro, amino, mono- or di-C₁₋₄ alkylamino, formyl, mercapto, C₁₋₄ alkyl-carbonyl, C₁₋₄ alkoxy-carbonyl, sulfo, C₁₋₄ alkylsulfonyl, carbamoyl, mono- or di-C₁₋₄ alkyl-carbamoyl, oxo, and thioxo.

Claim 4 (Currently Amended): ~~A compound~~ The compound according to claim 1,
wherein n is 1;

R₁ and R₂ are each independently a member selected from the group consisting of hydrogen, straight or branched chain C₁₋₆ alkyl, phenyl, naphthyl, hetaryl, C₁₋₆ alkyl substituted with at least one substituent, straight or branched chain C₁₋₆ alkylphenyl, phenyl substituted with at least one substituent, benzyl, and benzyl substituted with at least one substituent;

R₃ is a member selected from the group consisting of hydrogen, C₁₋₆ alkyl, aralkyl, C₁₋₆ alkyl substituted with at least one substituent, CO-R₅, or SO₂-R₅; CO-O-R₅, CO-N-R₄, and R₅;

R₄ and R₅ are each independently a member selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ alkyl substituted with at least one substituent, cycloalkyl, phenyl, and phenyl substituted with at least one substituent, aralkyl, benzyl, and benzyl substituted with at least one substituent; and

substituent is a member selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ alkoxy, C₁₋₄ alkylthio, phenoxyl, halophenoxy, phenylthio, pyridylthio, hydroxy, carboxy, cyano, nitro, amino, C₁₋₃ alkanoylamino, mono- or di-C₁₋₄ alkylamino, 4- to 6-membered cyclic amino, formyl, mercapto, C₁₋₄ alkyl-carbonyl, C₁₋₄ alkoxy-carbonyl, sulfo, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₃ alkanoyl, benzoyl, mono- or di-C₁₋₄ alkyl-carbamoyl, oxo, thioxo, and 5 to 10 membered heterocyclic.

Claim 5 (Currently Amended): ~~A compound~~ The compound according to claim 1,
wherein n is 1, and with reference to R₁₋₅, whenever the following are used;

alkyl is a straight or branched chain C₁₋₁₅;

alkenyl is a straight or branched chain C₂₋₁₈;

aryl is a carbomonocyclic aromatic or carbobicyclic aromatic;

cycloalkyl is a C₃₋₈ alkyl ring,

hetaryl is a heteromonocyclic aromatic or heterobicyclic aromatic containing 1 to 6 hetero-atoms selected from the group consisting of oxygen, sulfur and nitrogen;

aralkyl is a carbomonocyclic aromatic or carbobicyclic aromatic and substituted with a straight or branched chain C₁₋₁₅ alkyl;

hetaralkyl is a heteromonocyclic aromatic or heterobicyclic aromatic containing 1 to 6 hetero-atoms selected from the group consisting of oxygen, sulfur, and nitrogen and substituted with a straight or branched chain C₁₋₁₅ alkyl; and

substituent is a member selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ alkoxy, C₁₋₄ alkylthio, phenoxyl, halophenoxy, phenylthio, pyridylthio, hydroxy, carboxy, cyano, nitro, amino, C₁₋₃ alkanoylamino, mono- or di-C₁₋₄ alkylamino, 4- to 6-membered cyclic amino, formyl, mercapto, C₁₋₄ alkyl-carbonyl, C₁₋₄ alkoxy-carbonyl, sulfo, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₃ alkanoyl, benzoyl, mono- or di-C₁₋₄ alkyl-carbamoyl, oxo, thioxo, and 5 to 10 membered heterocyclic.

Claim 6 (Currently Amended): ~~A compound~~ The compound according to claim 1, wherein n is 1;

R₁ and R₂ are each independently a member selected from the group consisting of straight or branched chain C₁₋₆ alkyl, phenyl, benzyl, naphthyl, straight or branched chain C₁₋₆ alkyl substituted with at least one substituent, phenyl substituted with at least one substituent ~~substituent~~, and benzyl substituted with at least one substituent;

R₃ is a member selected from hydrogen, straight or branched chain C₁₋₆ alkyl, C₁₋₆ aralkyl, C₁₋₆ alkyl substituted with at least one substituent;

R₄ and R₅ are each independently a member selected from the group consisting of hydrogen, straight or branched chain C₁₋₆ alkyl, straight or branched chain C₁₋₆ alkyl substituted with at least one substituent, cycloalkyl, phenyl, phenyl substituted with at least one substituent, benzyl, and benzyl substituted with at least one substituent; and substituent is a member selected from the group consisting of methyl, halogen, halophenyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, t-butyl, and nitro.

Claim 7 (Currently Amended): ~~A compound~~ The compound according to claim 1,
wherein n is 1;

R₁ is a member selected from the group consisting of straight or branched chain C₁₋₆ alkyl, and phenyl;

R₂ is a member selected from the group consisting of phenyl, C₁₋₆ alkylphenyl, C₁₋₆ dialkylphenyl, C₁₋₆ alkoxyphenyl, halophenyl, dihalophenyl, and nitrophenyl;

R₃ is a member selected from hydrogen and straight or branched chain C₁₋₆ alkyl;

R₄ is phenyl substituted with at least one substituent selected from the group consisting of halogen, phenoxy, benzyloxy, halophenoxy, straight or branched chain C₁₋₆ alkyl, C₁₋₆ alkoxy, and halo-C₁₋₄ alkyl and;

[[R5]] R₅ is a straight or branched chain C₁₋₆ alkyl.

Claim 8 (Original): The compound of claim 1, wherein n is 1;

R₁ is phenyl or t-butyl;

R₂ is a member selected from the group consisting of methylphenyl, dimethylphenyl, t-butyl, methoxyphenyl, chlorophenyl, dichlorophenyl, fluorophenyl, and nitrophenyl;

R₃ is hydrogen;

R₄ is a phenyl substituted with at least one substituent selected from the group consisting of chlorine, fluorine, phenoxy, benzyloxy, chlorophenoxy, methoxy, ethoxy, and trifluoromethyl; and

R₅ is a methyl.

Claim 9 (Currently Amended): ~~A compound~~ The compound according to claim 1 ~~one of the claims 1 to 8~~, wherein said compound has an IC₅₀ less than 10 μ M in an *in vitro* inhibition of P I 3-K activity or an IC₅₀ less than 20 μ M in cellular inhibition of P I 3-K activity.

Claim 10 (Currently Amended): A pharmaceutical composition comprising the compound or a salt thereof according to ~~one of the claims 1 to 8~~ claim 1 and a pharmaceutically acceptable carrier.

Claim 11 (Currently Amended): A method of screening and characterizing the potency of a test compound as an inhibitor of phosphatidylinositol 3-kinase (PI 3-K) polypeptide, said method comprising ~~the steps of~~ (a) measuring activity of a PI 3-K polypeptide in the presence of a test compound according to claim 1 ~~one of the claims 1 to 8~~; and (b) comparing the activity of the PI 3-K polypeptide in the presence of the test compound to the activity of the PI 3-K polypeptide in the presence of an equivalent amount of a known PI 3-K inhibitor as a reference compound, wherein lower activity of the PI 3-K polypeptide in the presence of the test compound than in the presence of the reference compound indicates that the test compound is a more potent inhibitor than the reference compound, and higher activity of the PI 3-K polypeptide in the presence of the test compound than in the presence

of the reference compound indicates that the test compound is a less potent inhibitor than the reference compound.

Claim 12 (Currently Amended): A method to treat a disorder in which P I 3-K plays a role, comprising administering to a patient with said disorder an effective amount of the compound or a salt thereof according to ~~one of the claims 1 to 8~~ claim 1.

Claim 13 (Currently Amended): ~~A method~~ The method according to claim 12, wherein the disorder is a cancer or a disease of immunity and inflammation.

Claim 14 (Currently Amended): ~~A method~~ The method according to claim 12, wherein the disorder is disruption of PI 3-K function in leukocytes.

Claim 15 (Currently Amended): A method for inhibiting growth of cancer cells, comprising contacting said cancer cells with an effective amount of the compound or a salt thereof according to ~~one of the claims 1 to 8~~ claim 1.

Claim 16 (Original): The method according to claim 15, wherein said cancer cells are altered in PI 3-K mediated signaling via mutation in PTEN, amplification of the PIK3CA gene or mutations in PI 3-Kinase.

Claim 17 (Original): The method according to claim 15, wherein said cancers include breast, prostate, colon, lung, ovarian, and other cancers having altered PI 3-K activities.

Claim 18 (Currently Amended): A method for affecting PI 3-K mediated signaling in cells comprising contacting said cells with an effective amount of the compound or a salt thereof according to ~~one of the claims 1 to 8~~ claim 1.

Claim 19 (Original): The method according to claim 18, wherein said compounds affect PI 3-K mediated phosphorylation of Akt.

Claim 20 (New): A method for affecting PI 3-K mediated signaling in cells comprising contacting said cells with an effective amount of the compound or a salt thereof according to claim 2.